Equities

Viridian Therapeutics Inc

Viridian Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)22.50
  • Today's Change1.44 / 6.84%
  • Shares traded4.00
  • 1 Year change+31.96%
  • Beta1.0654
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy7
Outperform8
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 16 analysts offering 12 month price targets for Viridian Therapeutics Inc have a median target of 39.00, with a high estimate of 56.00 and a low estimate of 22.00. The median estimate represents a 73.33% increase from the last price of 22.50.
High148.9%56.00
Med73.3%39.00
Low-2.2%22.00

Earnings history & estimates in USD

On Aug 08, 2024, Viridian Therapeutics Inc reported 2nd quarter 2024 losses of -1.02 per share.
The next earnings announcement is expected on Nov 11, 2024.
Average growth rate+0.67%
Viridian Therapeutics Inc reported annual 2023 losses of -5.31 per share on Feb 27, 2024.
Average growth rate+23.24%
More ▼

Revenue history & estimates in USD

Miragen Therapeutics had 2nd quarter 2024 revenues of 72.00k. This missed the 86.00k consensus estimate of the 13 analysts following the company. This was 26.53% below the prior year's 2nd quarter results.
Average growth rate0.00%
Miragen Therapeutics had revenues for the full year 2023 of 314.00k. This was 82.28% below the prior year's results.
Average growth rate-4.19%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.